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background: Galectin-3 (Gal3) is implicated in the pathogenesis of cardiac fibrosis but is also increased with normal aging and renal disease. 
Because cardiac fibrosis is associated with HF with preserved ejection fraction (HFpEF), we hypothesized that elevated plasma Gal3 would identify 
patients with more advanced HFpEF.
Methods: 208 patients from the RELAX trial of sildenafil in HFpEF had Gal3 measured at enrollment. Pathophysiologic domains assessed included 
cardiac structure and function (echo), exercise performance (peak oxygen consumption (VO2) and ventilatory efficiency (VE/VCO2)), congestion 
(physical exam and NT-proBNP) and quality of life (Minnesota Heart Failure Questionnaire, MLHFQ). Analysis adjusted for covariates known to be 
associated with Gal3 levels in normal persons. Potential interaction between baseline Gal3 and treatment (sildenafil) effect on the RELAX primary 
endpoint (change in VO2) was tested.
results: Adjusting for age, sex and cystatin-C, Gal3 was not associated with severity of cardiac remodeling or dysfunction, exercise intolerance, 
congestion or quality of life impairment (Table). Gal3 did not identify patients who responded to PDE-5 inhibitors (interaction p = 0.53).
conclusion: In HFpEF, Gal3 was not independently associated with severity of pathophysiologic derangement and did not identify patients 
responding to PDE-5 inhibition. These findings are pertinent to efforts to modulate Gal3 or use Gal3 levels to predict treatment response in HFpEF.
Median values or % shown
Gal3 < 12.2 ng/ml
(n=69)
Gal3
12.2-15.9 ng/ml
(n=70)
Gal3 > 15.9 ng/ml
(n=69)
Unadjusted*
p value
Adjusted†
p value
LV dimension/BSA (mm/m2) 2.22 2.22 2.19 0.96 0.96
LV mass/height1.7 (g/m) 63.0 66.8 65.6 0.64 0.91
Relative wall thickness 0.38 0.40 0.45 0.006 0.71
Ejection fraction (%) 61 60 60 0.47 0.66
e’ (cm/s) 0.06 0.06 0.06 0.22 0.13
E/e’ 14.6 15.7 17.5 0.17 0.99
Deceleration time (ms) 181 190 183 0.95 0.94
Left atrial volume/BSA (ml/m2) 43.0 42.1 46.4 0.48 0.59
RV Systolic Pressure (mmHg) 41.0 37.0 45.0 0.19 0.24
Peak VO2 (ml/kg/min) 13.3 11.7 11.1 0.004 0.68
VE/VCO2 32.4 31.7 34.1 0.69 0.92
JVP > 13 cm (%) 18 16 18 0.78 0.88
≥ Moderate edema (%) 9 21 29 0.11 0.12
NT-proBNP (pg/ml) 524 727 1187 0.003 0.99
MLHFQ Score 44.0 45.5 39.5 0.30 0.80
*Kruskal-Wallis test
†Linear regression model adjusted for age, sex and cystatin-C with Gal3 analyzed as a three-level categorical variable
Abbreviations: Left (LV) or right (RV) ventricular, body surface area (BSA), jugular venous pressure (JVP) or see text
